ALAFOSS-01
Phase 1 Terminated
17 enrolled
Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Terminated
1 enrolled
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Phase 1 Terminated
29 enrolled
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
Phase 1 Terminated
12 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
21 enrolled
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Phase 1 Terminated
64 enrolled
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Phase 1 Terminated
30 enrolled
Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen
Phase 1 Terminated
4 enrolled
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
Phase 1 Terminated
16 enrolled 9 charts
MESO-PRIME
Phase 1 Terminated
5 enrolled 13 charts
Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease
Phase 1 Terminated
5 enrolled
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Phase 1 Terminated
42 enrolled
PRIMING
Phase 1 Terminated
2 enrolled 10 charts
A Study of PHN-010 in Patients With Advanced Solid Tumors
Phase 1 Terminated
26 enrolled
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
79 enrolled 24 charts
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
Phase 1 Terminated
9 enrolled
This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091
Phase 1 Terminated
8 enrolled 10 charts
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
Phase 1 Terminated
227 enrolled
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer
Phase 1 Terminated
41 enrolled
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Phase 1 Terminated
30 enrolled
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Phase 1 Terminated
27 enrolled
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Phase 1 Terminated
65 enrolled 52 charts
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Phase 1 Terminated
29 enrolled
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Phase 1 Terminated
122 enrolled
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
23 enrolled
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Phase 1 Terminated
75 enrolled
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
SABRseq
Phase 1 Terminated
13 enrolled 14 charts
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Phase 1 Terminated
44 enrolled
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Phase 1 Terminated
44 enrolled
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
Phase 1 Terminated
4 enrolled
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Phase 1 Terminated
6 enrolled
AM-003
Phase 1 Terminated
5 enrolled
A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)
Phase 1 Terminated
22 enrolled
A Study to Investigate LYL797 in Adults With Solid Tumors
Phase 1 Terminated
57 enrolled
Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
Phase 1 Terminated
13 enrolled
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
Phase 1 Terminated
12 enrolled
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Phase 1 Terminated
60 enrolled
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Phase 1 Terminated
3 enrolled 13 charts
RAPTOR
Phase 1 Terminated
27 enrolled
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Phase 1 Terminated
241 enrolled
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Phase 1 Terminated
106 enrolled
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Phase 1 Terminated
63 enrolled
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer
Phase 1 Terminated
14 enrolled